Obsidian Therapeutics aims to show its TIL cell therapy has advantages over an Iovance Biotherapeutics TIL therapy marketed for treating melanoma. Obsidian’s merger with Galera Therapeutics will give it a public listing and a private placement to support clinical development of the combined company’s cancer drug pipeline.
Vertex Pharmaceuticals is collaborating with Obsidian Therapeutics to develop up to five new gene editing therapies. Obsidian’s technology precisely controls protein expression, a capability the partners plan to apply to several undisclosed serious diseases.
Enterprise EHR boosts scalability, interoperability, and governance for large healthcare systems.
In a recent interview, executives from two early-stage biopharma companies said that off-the-shelf approach is the only way to drive down the cost of novel cell and gene therapies like CAR-T.
The company said Friday morning that it would partner with two companies, Kyn Therapeutics and Obsidian Therapeutics.